INO-8875, a potent and highly selective adenosine mimetic acting at the A1 receptor, is in Phase 2 clinical development for glaucoma. The drug candidate has completed Phase 1 and Phase 2 trials in patients, in which trabodenoson eye drops were administered to the eye. Treatment with trabodenoson was well tolerated and the drug was shown to significantly reduce intraocular pressure (IOP) in glaucoma and OHT patients. After 28 days of trabodenoson mono-therapy the efficacy achieved was in the range of the market leading prostaglandins, such as latanoprost. Of interest, efficacy was still increasing with dose up to the highest dose tested indicating that higher doses may be more efficacious still. The data also showed continued improvement in IOP lowering with time on therapy. Trabodenoson is currently being evaluated in a multiple-dose Phase 2 trial in combination with a prostaglandin. For a more detailed description of the trial protocol, please visit clinicaltrials.gov

Preclinical studies in multiple different animal models with trabodenoson have demonstrated a consistent IOP-lowering effect. The compound appears to work primarily by increasing the outflow of ocular fluid (aqueous humor) via the trabecular meshwork pathway, the main pathway used by healthy eyes to maintain normal IOP. As a new mechanism of action, trabodenoson has the potential to provide significant benefit by reducing intraocular pressure, and ideally the attending optic nerve neuropathy that leads to vision loss in patients with glaucoma.

INO-8875 MOA Glaucoma